Last reviewed · How we verify
Effects of the Novel Beta-adrenergic Antagonist Nebivolol (Bystolic) on Prehypertensive Subjects at Genetic Risk of Hypertension: Implications for Inflammation, Endothelial Dysfunction, and Oxidative Stress.
The investigators aim to evaluate subjects at high risk of future development of hypertension, those with a family history of hypertension and/or that already have high normal(SBP 120-139 mmHg or DBP 80-89 mmHg) blood pressure. The investigators plan to investigate whether these subjects have the same markers (such as microscopic protein in the urine or C-reactive protein in the blood) in the blood and urine that people with high blood pressure have, and whether they are improved before and after taking the beta-blocker nebivolol.
Details
| Lead sponsor | University of California, San Diego |
|---|---|
| Phase | Phase 4 |
| Status | COMPLETED |
| Enrolment | 50 |
| Start date | 2010-07 |
| Completion | 2013-06 |
Conditions
- Pre-hypertension
- Hypertension
Interventions
- Nebivolol
Primary outcomes
- Aortic Systolic Blood Pressure (SBP) — Basline (visit 1) and 8 weeks (visit 2)
- Aortic Diastolic Blood Pressure (DBP) — Basline (visit 1) and 8 weeks (visit 2)
- Aortic Mean Arterial Pressure (MAP) — Basline (visit 1) and 8 weeks (visit 2)
- Aortic Pulse Pressure — Basline (visit 1) and 8 weeks (visit 2)
- Aortic Augmentation Pressure — Basline (visit 1) and 8 weeks (visit 2)
- Aortic Augmentation Index for Heart Rate — Basline (visit 1) and 8 weeks (visit 2)
Countries
United States